Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
11.78
-0.28 (-2.32%)
After Hours: 11.78 0.00 (0.00%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.45 - 12.03
52 week 8.95 - 17.33
Open 12.01
Vol / Avg. 2.96M/1.35M
Mkt cap 1.43B
P/E     -
Div/yield     -
EPS -2.38
Shares 121.17M
Beta 1.53
Inst. own 97%
Jul 21, 2014
Q2 2014 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jun 3, 2014
IRONWOOD PHARMACEUTICALS INC Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 29, 2014
Q1 2014 Ironwood Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 29, 2014
Q1 2014 Ironwood Pharmaceuticals Inc Earnings Conference Call - 8:30AM EDT - Add to calendar
Mar 3, 2014
IRONWOOD PHARMACEUTICALS INC at Cowen Health Care Conference
Feb 12, 2014
IRONWOOD PHARMACEUTICALS INC at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1033.31% -1192.31%
Operating margin -929.00% -1101.36%
EBITD margin - -1050.10%
Return on average assets -68.95% -107.22%
Return on average equity -340.62% -299.34%
Employees 534 -
CDP Score - -

Address

301 BINNEY STREET
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Michael J. Higgins Chief Financial Officer, Chief Operating Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 58
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 55
Bio & Compensation  - Reuters
Michael L. Hall M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Julie H. McHugh Director
Age: 48
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 74
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters
David A. Ebersman Independent Director
Age: 44
Bio & Compensation  - Reuters